Childhood Epilepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. Seizures result from abnormal electrical discharges in the brain and vary in their manifestations, from the brief staring spells that are characteristic of absence seizures, to full-body convulsions known as tonic-clonic seizures. Seizures in children are among the most common neurological disorders.
The childhood epilepsy market report includes an assessment of the pipeline and the clinical and commercial landscapes of childhood epilepsy, along with an analysis of key market events and the future competitive environment.
What are the market dynamics in the childhood epilepsy therapeutics industry?
Focal (partial) seizures are the most frequent seizure type at all ages, but early-onset epilepsies, particularly those with infancy onset, are characterized by higher proportions of generalized seizures and epileptic spasms. Early-onset epilepsies are more likely to have a demonstrable cause, with structural and genetic causes being the most common. This shows the importance of including neuroimaging and genetic investigations in clinical care, especially for early-onset epilepsies. Childhood epilepsy has a large spectrum of clinical manifestations, and many other conditions may resemble epilepsy. This often makes the diagnostic process challenging, with a considerable risk of misdiagnosis.
The incidence of childhood epilepsy varies between industrialized countries and developing ones. Higher incidence is reported from underdeveloped countries, particularly from rural areas. Incidence of childhood epilepsy is higher in males than in females. The incidence is consistently reported to be highest in the first year of life and declines to adult levels by the end of the first decade. The mortality rate in people affected by epilepsy is 2–4 times higher than the rest of the population, and 5–10 times higher in children.
The mainstay of epilepsy treatment revolves around the use of anti-epileptic drugs (AEDs) to treat and prevent the occurrence of seizures. A multitude of AED products are currently available, many of which are now available as inexpensive generics, making the childhood epilepsy market competitive and crowded. The choice of AED to prescribe can be difficult and depends on several factors such as type of seizures or epilepsy syndrome, age, comorbidities, drug interactions, efficacy, side-effect profile, and cost. For focal seizures, carbamazepine is traditionally prescribed as the first-line treatment. However, most patients soon switch to similarly efficacious therapies with better tolerability. These include levetiracetam, lamotrigine, as well as later-generation versions of carbamazepine such as oxcarbazepine. Sodium valproate and topiramate are also commonly used for focal seizures.
Which are the key regions in the childhood epilepsy market?
The US, Europe, and Asia-Pacific are the key regions in the childhood epilepsy market. The US has the highest number of clinical trials for childhood epilepsy, followed by Europe and Asia-Pacific.
Which are the key phases in the childhood epilepsy market?
The key phases in the childhood epilepsy market include phase I, phase II, phase III, phase IV, phase I/II, and phase II/III.
There are 68 ongoing/planned Phase 0-Phase IV interventional studies being conducted for childhood epilepsy, with the majority in Phase II. The high number of completed Phase III trials highlights the mature nature of the childhood epilepsy market.
Childhood epilepsy market, by phase
For more phase insights, download a free sample
What are the top targets for drug development in the childhood epilepsy market?
The gamma-aminobutyric acid type A receptor subunit, G protein coupled receptor 55 (GPR55), voltage gated sodium channel (SCN, and 5-hydroxytryptamine receptor 2C (5 HT2C) are the top targets for drug development in the childhood epilepsy market.
The gamma-aminobutyric acid type A receptor subunit (GABA(A) receptor) has emerged as a key target for most of the pipeline candidates within the childhood epilepsy space.
What are top drugs in the childhood epilepsy market?
Rufinamide, Clobazam, Cannabidiol, Sulthiame, Corticotropin, Cosyntropin are the top drugs in the childhood epilepsy market.
Childhood epilepsy market, by drugs
For more drug insights, download a free sample
Who are the major sponsors in the childhood epilepsy market?
Abbott Laboratories, GW Pharmaceuticals, Takeda Pharmaceutical, Eisai, UCB, Zogenix, Rinpharm are few of the top sponsors in the childhood epilepsy market.
Abbott Laboratories ranks as the top sponsor in childhood epilepsy clinical research with 18 clinical trials. After Abbott, the most active sponsors of childhood epilepsy clinical trials are SK Biopharm and Rinpharm.
Childhood epilepsy market, by sponsor
To know more about key sponsors, download a free sample
Market report scope
Top drugs | Rufinamide, Clobazam, Cannabidiol, Sulthiame, Corticotropin, Cosyntropin |
Key Phases | Phase I, phase II, phase III, phase IV, phase I/II, and phase II/III |
Key regions | The US, Europe, and Asia-Pacific |
Key targets | Gamma-Aminobutyric Acid Type A Receptor Subunit, G Protein Coupled Receptor 55 (GPR55), Voltage Gated Sodium Channel (SCN, and 5-Hydroxytryptamine Receptor 2C (5 HT2C) |
Key sponsors | Abbott Laboratories, GW Pharmaceuticals, Takeda Pharmaceutical, Eisai, UCB, Zogenix, Rinpharm |
Scope
- GlobalData’s Childhood Epilepsy: Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global childhood epilepsy market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global childhood epilepsy market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which are the key regions in the childhood epilepsy market?
The US, Europe, and Asia-Pacific are the key regions in the childhood epilepsy market.
-
Which are the key phases in the childhood epilepsy market?
The key phases in the childhood epilepsy market include phase I, phase II, phase III, phase IV, phase I/II, and phase II/III.
-
What are the top targets for drug development in the childhood epilepsy market?
The gamma-aminobutyric acid type A receptor subunit, G protein coupled receptor 55 (GPR55), voltage gated sodium channel (SCN, and 5-hydroxytryptamine receptor 2C (5 HT2C) are the top targets for drug development in the childhood epilepsy market.
-
Who are the major sponsors in the childhood epilepsy market?
Abbott Laboratories, GW Pharmaceuticals, Takeda Pharmaceutical, Eisai, UCB, Zogenix, Rinpharm are few of the top sponsors in the childhood epilepsy market.
-
What are the top drugs in the childhood epilepsy market?
Rufinamide, Clobazam, Cannabidiol, Sulthiame, Corticotropin, Cosyntropin are the top drugs in the childhood epilepsy market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.